通过定量蛋白质组学分析鉴定血浆纤连蛋白水平预测慢性乙

StephenW

Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B
Fen Liu, Wai-Kay Seto, Danny Ka-Ho Wong, Fung-Yu Huang, Ka-Shing Cheung, Lung-Yi Mak, Rakesh Sharma, Saisai Zhang, James Fung, Ching-Lung Lai ... Show more
The Journal of Infectious Diseases, Volume 220, Issue 6, 15 September 2019, Pages 940–950, https://doi.org/10.1093/infdis/jiz223
Published:
06 May 2019
Article history

    Cite
    Permissions Icon Permissions
    Share

Abstract
Background

Seroclearance of hepatitis B surface antigen (HBsAg) is a potentially achievable target of chronic hepatitis B (CHB). Plasma proteins relevant to HBsAg seroclearance remain undetermined.
Methods

We prospectively recruited treatment-naive CHB patients with spontaneous HBsAg seroclearance and matched HBsAg-positive controls. Plasma protein profiling was performed using isobaric tags for relative and absolute quantitation-based proteomics, with the expression of candidate proteins validated in a separate cohort. The predictive value of fibronectin was assessed at 3 years, 1 year (Year -1) before, and at the time (Year 0) of HBsAg seroclearance.
Results

Four hundred eighty-seven plasma proteins were identified via proteomics, with 97 proteins showing altered expression. In the verification cohort (n = 90), median plasma fibronectin levels in patients with HBsAg seroclearance was higher than in controls (P = .009). In the longitudinal cohort (n = 164), patients with HBsAg seroclearance, compared with controls, had a higher median fibronectin levels at Year -1 (413.26 vs 227.95 µg/mL) and Year 0 (349.45 vs 208.72 µg/mL) (both P < .001). In patients with an annual HBsAg log reduction >0.5, Year -1 fibronectin level achieved an area under the receiving operator characteristic of 0.884 in predicting HBsAg seroclearance.
Conclusions

Using proteomics-based technology, plasma fibronectin may be associated with HBsAg seroclearance and a potential predictor of “functional cure”.
biomarker, functional cure, HBsAg, HBV, iTRAQ
Topic:

    fibronectins hepatitis b surface antigens hepatitis b, chronic plasma proteomics

Issue Section:
Vaccines

StephenW

通过定量蛋白质组学分析鉴定血浆纤连蛋白水平预测慢性乙型肝炎中乙型肝炎表面抗原血清清除率
Fen Liu，Wai-Kay Seto，Danny Ka-Ho Wong，Huang-Yu Huang，Ka-Shing Cheung，Lung-Yi Mak，Rakesh Sharma，Saisai Zhang，James Fung，Ching-Lung Lai ...显示更多
Journal of Infectious Diseases，Volume 220，Issue 6,15 September September，Pages 940-950，https：//doi.org/10.1093/infdis/jiz223
发布时间：
2019年5月6日
文章历史

    引用
    权限图标权限
    分享

抽象
背景

乙型肝炎表面抗原（HBsAg）的血清清除是慢性乙型肝炎（CHB）的潜在可实现目标。与HBsAg血清清除相关的血浆蛋白仍未确定。
方法

我们前瞻性地招募了自发性HBsAg血清清除和匹配的HBsAg阳性对照的初治CHB患者。使用同量异位标签进行血浆蛋白质分析，用于基于相对和绝对定量的蛋白质组学，候选蛋白质的表达在单独的群组中得到验证。在HBsAg血清清除前3年，1年（1年）和HBsAg血清清除时间（0年）评估纤连蛋白的预测值。
结果

通过蛋白质组学鉴定了477种血浆蛋白，其中97种​​蛋白表现出改变的表达。在验证队列（n = 90）中，HBsAg血清清除患者的血浆纤维连接蛋白中位数水平高于对照组（P = .009）。在纵向队列（n = 164）中，与对照组相比，HBsAg血清清除率患者在第-1年（413.26 vs227.95μg/ mL）和0年（349.45 vs208.72μg/ mL）的纤维连接蛋白水平中位数更高（均为P <.001）。在年度HBsAg对数减少> 0.5的患者中，年-1纤连蛋白水平在接受操作者特征0.884下达到预测HBsAg血清清除率的面积。
结论

使用基于蛋白质组学的技术，血浆纤连蛋白可能与HBsAg血清清除率和“功能性治愈”的潜在预测因子有关。
生物标志物，功能性治疗，HBsAg，HBV，iTRAQ
话题：

    纤连蛋白乙型肝炎表面抗原乙型肝炎，慢性血浆蛋白质组学

问题部分：
疫苗